Todd Carter, PhD (CSO at Voyager Therapeutics) talks with incoming Communications Committee Chair Lynnea Olivarez about changes in the approach to developing gene therapies for CNS disorders like Huntington's disease.

mRNA-based CAR T cell engineering with Norman Drzeniek and Niklas Kotzian
32:35

The Issue - Evolving Patient Access to CGTs via Innovation in Medicaid Reimbursement Models with Melissa Majerol
35:33

Cas9-CLIPT-mediated integration of large transgenes with Krishanu Saha, Anna Tommasi, and Dan Cappabianca
46:57